Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy: association with regression of hepatic fibrosis

Tsushima, Hirofumi; Kawata, Satoshi; Tamura, Shinji; Ito, Nobuyuki; Shirai, Yoshio; Kiso, Shinichi; Doi, Yoshinori; Yamada, Akira; Oshikawa, Osamu; Matsuzawa, Yūji

doi:10.1016/s0168-8278(99)80001-4

Cited by 94 publications

(59 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 Our data on intrahepatic TGF-b1 expression after the treatment are also consistent with previous studies on a limited number of cases, 40 and we confirmed the absence of any correlation between TGF-b expression and the degree of liver damage. 41 The functional interactions between TGF-b1 and NF-kB in chronic hepatitis C, and how they may be affected by antiviral therapy, are not known.…”

Section: Discussionsupporting

confidence: 92%

Effects of interferon plus ribavirin treatment on NF-κB, TGF-β1, and metalloproteinase activity in chronic hepatitis C

et al. 2006

View full text Add to dashboard Cite

Little is known about the cellular and molecular mechanisms underlying the effects of anti-viral therapy on the regression of liver inflammation and fibrosis in chronic hepatitis C. The aim of this study was to evaluate the effects of interferon alpha and ribavirin in combination therapy on the tissue expression of nuclear-factor kB (NF-jB) (a transcription factor coordinating the expression of stress genes involved in immune response and inflammation), of the polypeptide transforming growth factor beta-1 (TGF-b1) and matrix metalloproteinases 1 (MMP-1) (both of which play an important part in the pathological process of liver fibrogenesis), and on the serum levels of soluble TGF-b1, tissue inhibitors of metalloproteinases (TIMP)-1, and active endogenous MMP-2 and MMP-9 in paired (pre-and post-treatment) liver biopsy and serum samples of subjects with chronic hepatitis C. Serum levels of TGF-b1, TIMP-1, MMP-2, and MMP-9 were evaluated by enzyme-linked immunosorbent assay. Liver expression of muscle-specific a-actin, NF-jB, TGF-b1, and MMP-1 was studied immunohistochemically using commercially available mono-and polyclonal antisera in an avidin-biotin complex method. Combination therapy induced a reduction in the liver expression of TGF-b and NF-jB and an increased expression of MMP-1, regardless of the virological response to the treatment. The greater expression of MMP-1 and lesser expression of NF-jB were both associated with an improvement in fibrosis score. These effects paralleled the significant increase in soluble MMP-9/TIMP-1 ratio in post-therapy sera. Combination therapy with interferon and ribavirin affects the tissue expression of TGF-b-1 and NF-jB and favors metalloproteinase activity, and may thereby modulate hepatic fibrogenetic events.

show abstract

Section: Discussionsupporting

confidence: 92%

Effects of interferon plus ribavirin treatment on NF-κB, TGF-β1, and metalloproteinase activity in chronic hepatitis C

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated the anti-fibrogenic effect of interferon (Muriel, 1996) via inhibiting TGF-β expression (Castilla et al, 1991;Tsushima et al, 1999;Chang et al, 2005), which decreases hepatic stellate cell activation and stimulates apoptosis (Chang et al, 2005). In the current study we demonstrate that the coadministration of JAT along with interferon and ribavirin can revert liver fibrosis more effectively.…”

Section: Discussionsupporting

confidence: 63%

Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats

Abdel-Hamid

Wahid²,

Nazmy³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The role of this factor in fibrosis development has been studied for several years [5][6][7][8][9][10] . Results of those studies confirm the existence of a connection between the factor's concentration in the blood and progression of liver lesions [8][9][10] , as well as reduction of those concentrations following treatment leading to the decrease of fibrosis stage [10] . Vascular endothelial growth factor (VEGF) stimulates angiogenesis both in regular conditions and in neoplastic processes [11][12][13][14][15] .…”

Section: Rapid Communicationmentioning

confidence: 99%

Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C

Janczewska

Marek²,

Kajdaniuk³

et al. 2006

WJG

View full text Add to dashboard Cite

Reduced plasma transforming growth factor-β1 levels in patients with chronic hepatitis C after interferon-α therapy: association with regression of hepatic fibrosis

Cited by 94 publications

References 36 publications

Effects of interferon plus ribavirin treatment on NF-κB, TGF-β1, and metalloproteinase activity in chronic hepatitis C

Effects of interferon plus ribavirin treatment on NF-κB, TGF-β1, and metalloproteinase activity in chronic hepatitis C

Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats

Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C

Contact Info

Product

Resources

About